// App-Quantinova.ai

3625 : SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Researchers

Presenter

  • Donna E. Hogge

Principal Investigators

  • David A. Rizzieri

  • Rui-yu Wang

  • Jorge E. Cortes

  • Kenneth Hoberman

  • Michael Szarek

  • Eric Rowinsky

  • Ivan Bergstein

  • Hagop M. Kantarjian

  • Arthur E. Frankel

  • Thomas P. Cirrito

  • Steven M. Kornblau

  • Gautam Borthakur

  • Carol Bivins

  • Guillermo Garcia-Manero

  • Tapan M. Kadia

  • Farhad Ravandi

  • Michael Andreeff

Medical Centers

  • Lymphoma, MD anderson Cancer Center, Houston, TX

  • Division of Hematology, University of British Columbia, Vancouver, BC, Canada

  • SUNY Downstate Medical Center, Brooklyn, NY

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

Locations

  • United States

  • Canada

Companies

  • Stemline Therapeutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematologic and solid malignancies

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Interleukin

  • Tagraxofusp

Outcome

  • N/A

Study Design

  • randomized

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved